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Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalci-
trant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial
enrolled 19 patients. We observed overall and complete response rates of 84.2% and
42.1% (with no significant differences between stage I-IIA and IIB-IV patients), and
11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS),
event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS,
EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo
seems to be an active and safe principle that should be used in plurirelapsed, early
stage-MF and in combination with other chemotherapeutic agents in advanced and
aggressive CTCLs.
Key words: pegylated liposomal doxorubicin, primary cutaneous T-cell lymphomas,
mycosis fungoides, Sézary syndrome.
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Brief Report
ABSTRACT
Doxorubicin is an effective agent usedin the treatment of non-Hodgkin’slymphoma. However, its therapeu-
tic index is low due to frequent toxicity thus
limiting its use. Pegylated liposomal doxoru-
bicin (Peg-Doxo) represents a new
chemotherapy delivery system which can
improve tolerability and the effectiveness of
the anthracycline concentration inside the
tumour. Recently, the efficacy and safety of
Peg-Doxo have been tested both as single
agent and in combination with other cyto-
toxic agents in a large spectrum of solid
tumors and hematological malignancies1-3
with remarkable results. It has also been
used in cutaneous T-cell lymphomas
(CTCLs) refractory to prior therapy or in
advanced stages, when treatment is particu-
larly unsatisfactory.4 Experience with Peg-
Doxo in this group of patients is encouraging
but still limited to studies of single cases of
groups of a maximum of 34 patients in the
largest series.5-7 This led therefore to the
present prospective study on advanced,
relapsed and refractory primary CTCLs
using Peg-Doxo as single agent. Results are
compared with previous experiences with
this drug and other chemotherapeutic
options reported in literature.
Design and Methods
Between May 2002 and May 2005, a
prospective, multicenter, phase II clinical
trial of monochemotherapy with Peg-Doxo
was performed in patients with advanced,
relapsed and refractory primary CTCLs. The
protocol was approved by local ethic com-
mittees and all patients gave their written
informed consent. Patients aged ≥18 with a
performance status (PS)=0-1 according to
WHO-ECOG performance score, or aged
≥75 with a 100% PS=0 were included.
Patients with other neoplasms, infections,
cyclothymic syndromes, autoimmune disor-
ders, hepatic, cardiac, respiratory or renal
diseases, allergy to anthracyclines, previous
administration of a cumulative anthracycline
dose >200 mg/m2, administration of radio-
or chemo-therapy within 4 weeks before
starting Peg-Doxo, abnormal blood counts
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(i.e. leukocyte <3.0×109/L, platelet <100×109/L and Hb
<10 g/dL) ) were excluded. Pregnant or lactating women
were also excluded and both men and women with
reproductive potential were required to use an approved
method of contraception. 
Pre-treatment evaluation included a comprehensive
study of clinical history, physical examination (evalua-
tion, mapping and measurement of skin lesions), and a
revision of histological, immunophenotypic and molecu-
lar features according to the recently published WHO-
EORTC classification scheme.8 Complete blood cell
count, confirmation of any circulating Sézary cells in
peripheral blood (PB) smears, routine laboratory tests
including renal and liver function, LDH and β2
microglobulin serum levels, thyroid hormones, anti-
nuclear, anti-DNA and anti-thyroid antibodies, PB
mononuclear cell immunophenotyping, echocardiogram,
a thoraco-abdominal-pelvic CT scan and a bone marrow
trephine biopsy were obtained at study entry. TCR-Vβ
flow cytometry and PCR for TCRγ and TCRδ were per-
formed on PB specimens from patients with Sézary
Syndrome (SS). Disease was staged according to the
TNM classification for Mycosis Fungoides (MF), the cri-
teria proposed by the International Society for
Cutaneous Lymphoma for SS, and the Ann Arbor classi-
fication for CTCLs other than MF.  
Peg-Doxo (Caelyx® Schering-Plough) was administered
every 4 weeks at the dosage of 20 mg/m2 during a 1-hour
intravenous infusion, using antiemetic prophylaxis
before infusion. Oral pyridoxine 300 mg was adminis-
tered daily from the beginning of Peg-Doxo treatment
until 1 month after its discontinuation to prevent the pal-
mar-plantar erythrodysesthesia (PPE). Blood and urine
parameters were monitored before each Peg-Doxo infu-
sion and a complete blood cell count was performed
weekly. Physical examination and assessment of skin
lesions were carried out before each Peg-Doxo infusion
until the end of treatment, and thereafter at one month,
at two months, and then every three months.
All patients receiving at least one cycle of Peg-Doxo
were considered evaluable for assessment of response
and toxicity. Response to treatment was defined as com-
plete remission (CR), very good partial remission
(VGPR), partial remission (PR), minor response (mR), sta-
ble disease (SD), and progressive disease (PD) according
to published criteria.9 Response was defined after blind
assessment by two independent observers, with CR and
PR lasting at least 4 weeks. SS response was assessed by
the measurement of clinically confirmed disease in the
skin and lymph nodes,9 and on the changes of CD4+ T-
cell subsets and clones in PB.4 Toxicity was carefully
monitored and graded by a medical interview, physical
examination and laboratory tests.10  Patients’ characteris-
tics and descriptive data were expressed as median and
range for continuous variables and by frequency tabula-
tions for categorical variables. Factors affecting achieve-
ment of complete remission and progressive disease
were assessed using the χ2 test or Fisher’s exact test for
contingency tables. Overall survival (OS) was calculated
from the time of the enrolment to death or the last fol-
low-up. Event-free survival (EFS) was calculated from the
time of the enrolment to any event including death from
any causes and PD. Progression-free survival (PFS) was
calculated from time of response to PD. Survival curves
were plotted using the Kaplan-Meier method.
Differences between the curves were assessed using the
log-rank test. Statistical significance was set at p<0.05.
Results and Discussion 
Patients’ characteristics are presented in Table 1 (online
appendix). They showed a median age of 67 yrs., a preva-
lence of male sex (14 men and 5 women) and II B-IV
stage. Most (68%) had MF at various stage, including the
folliculotropic variant (23%) and MF transformed into
large-cell lymphoma (23%). Sixteen percent of patients
had SS and 16% peripheral T-cell lymphoma-unspecified
(PTCL–U). All patients had received other therapies
before Peg-Doxo. These ranged from topical or oral
steroids, PUVA therapy, systemic retinoids, immunother-
apy with interferon-α (IFN-α), radiotherapy and various
systemic chemotherapy regimens (gemcitabine, daunox-
ome, chlorambucil, ATRA, fludarabine, mitoxantrone,
2CdA, VNCOP, CHOP, DHAP). One patient also
received immunomagnetic purged autologous bone mar-
row transplantation. MF patients’ staging was IB in 2/13
patients, IIA in 2/13, IIB in 5/13, IIIA in 1/13, and IVB in
3/13. PTCL-U patients’ staging was Ann Arbor IV. The
majority of patients had multiple, generalised skin
lesions (79%),  10.5% multiple but localized, 10.5% a
single large lesion. Skin lesions were tumors in 47.4% of
patients, erythroderma in 21%, patches in 15.8%, and
plaques in 15.8%. The median time from initial CTCL
diagnosis and the start of Peg-Doxo treatment was 43
months (range 1-252). 
Overall, 101 infusions of Peg-Doxo 20 mg/m2 were
administered. After a median of 6 courses of Peg-Doxo
(range 2-8), 8/19 patients achieved a CR (42.1%), 5
patients a VGPR (26.3%) and 3 patients a PR (15.8%).
Overall response rate (ORR) was therefore 84.2% (16/19
patients). The median time to the maximal response was
3 months (range 2-8). CR was obtained in 1/4 stage I-IIA
compared with 7/15 stage IIB-IV patients. The achieve-
ment of a CR was not statistically associated with an ear-
lier stage. These figures are even more prominent if only
MF patients are considered, 1/4 stage I-IIA compared
with 6/9 stage IIB-IV. CR was also reached in 1/3 SS
patients. Three patients (1 MF IIIA, 2 SS) showed no ben-
efit from the treatment. Of these, the MF patient experi-
enced a PD after 2 courses of Peg-Doxo, was then refrac-
tory to fludarabine (6 courses) and oral bexarotene, but
obtained a VGPR with alemtuzumab. The 2 SS patients
showed a SD and a mR after 6 courses of Peg-Doxo,
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were similarly unresponsive to extracorporeal photo-
pheresis (ECP), IFN and fludarabine (6 courses), yet
achieved a PR with oral chlorambucil and a VGPR with
oral bexarotene respectively.  Peg-Doxo monotherapy
was successfully tolerated, as overall adverse effects
were observed in 5 patients (26%) and grade III-IV toxi-
city only occurred in 2 patients (11%) (Table 1, online
appendix). Therapy was discontinued after 2 courses and
not resumed in one patient with PR (voluntary suspen-
sion) and in one with VGPR (grade III capillary leakage
syndrome). None of the remaining patients decreased or
delayed the dose. Hematological toxicity was mild with
only one case of grade >II neutropenia, which was suc-
cessfully treated with granulocyte colony-stimulating
factor (G-CSF). No patients experienced neutropenic
sepsis, herpes virus or other opportunistic infections.
There were no deaths from grade II gastrointestinal tox-
icity observed in two patients, and grade I PPE in one.
After a median follow-up of 22.6 months from enrol-
ment (range 3.4-45.9), 3 patients had only minor events.
These were minimal recurrences with limited skin dis-
ease responsive to topical steroids. Nine patients had
major events/PD. These included 4 PD and 5 significant
clinical relapses requiring other systemic therapies. At
the last follow-up (September 2005), 12 patients were
alive (6 in VGPR/PR and 2 in CR) and 7 dead, 2 for PD
and 5 for non-related causes to the disease (case 11, renal
carcinoma; case 13, acute myeloid leukaemia; case 15,
colonic carcinoma; case 18, pulmonary edema; case 19,
pulmonary fibrosis; Table 1, online appendix). Median OS,
EFS and PFS were 34, 18 and 19 months respectively. OS,
EFS and PFS rates at 46 months were 44%, 30% and
37% respectively. (Figures 1 A, B and C). Stage was not
found to be significantly associated with PFS. This study
confirms previous reports5-7 which demonstrate that Peg-
Doxo is a well tolerated, safe and effective drug in the
treatment of advanced and relapsed CTCLs, often refrac-
tory to standard therapies. Adverse events were
observed in 26% patients, yet grade III-IV in only 11%.
We observed CR and OR rates similar to the largest
study7 (42.1% vs 44%, 84.2% vs 88%), but a longer OS
and EFS (34 vs 17.8, 18 vs 12 months). This was in spite
of the fact that our series included a higher proportion of
III-IV stages (53% vs 38%), of SS (16% vs 3%), and
PTCL-U (16% vs 6%) cases. Furthermore, a high propor-
tion of patients (79%) had multiple generalised skin
lesions. Nodules and erythroderma were present in
47.4% and 21% of patients respectively. In spite of the
doubts raised about the efficacy of the drug in patients
previously treated by chemotherapy, our series indicates
that Peg-Doxo is effective in patients heavily pretreated
with chemotherapy. These represented 47% of our
cases. It is worth emphasizing that disease stage did not
influence either CR or PFS. This was confirmed even
when only MF patients were considered, with 6/9 stage
IIB-IV achieving a CR. 
The clinical benefits of Peg-Doxo in this study are to
be considered satisfactory even when compared to the
most used and effective regimens.11-19 However, the
reported data have been obtained in different decades
and different patient selection and staging criteria have
been adopted (Table 2, online appendix). The study on
BCPE (bleomycin, cyclophosphamide, prednisone and
etretinate) reported a higher response rate (CR 85%, OR
90%)11 and the study on CAVE (endoxan, doxorubicin,
etoposide, vincristin) combined with electron-beam irra-
diation showed a duration of response longer than 12
months combined with a higher OS.12 But apart from
these studies, monochemotherapy with Peg-Doxo
seems to be more effective than all the other treatment
modalities. like VICOP-B,13 EPOCH,15 CVP,16 CHOP and
CHOP-like17 regimens, and alemtuzumab14 or gemc-
Figure 1. A-C. Results of survival analysis. A. OS curve calculated
from time of enrolment to death or the last follow-up. Median OS
is 34 months. At 46 months, 44% of patients are still alive. B.
EFS curve calculated from time of enrolment to any event, pro-
gressive disease and death from any causes or progressive dis-
ease. Median EFS is 18 months. At 46 months, 30% of patients
are still event-free. C. PFS curve calculated from time of the
response to major events/progressive disease (PD). Median PFS
is 19 months. At 46 months, 37% of patients are still progres-
sion-free.
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itabine18 monotherapy. As far as life expectancy is con-
cerned, it is difficult to verify if Peg-Doxo obtained a real
survival benefit by comparing our data to the disease-
specific and progression-free survival reported in a large
series of 309 MF managed with standard therapy.19 This
study has only a limited number of cases in each disease
stage and patient follow-up is much shorter. Therefore,
in spite of the encouraging results, additional research is
needed to help define the role of Peg-Doxo in the treat-
ment of CTCLs. Given the unsatisfactory grade of rec-
ommendation and level of evidence assigned to all
chemotherapies for second-line treatment of the stage IIB
to IV MF and SS,4 only appropriate clinical trials on a larg-
er series would allow evidence-based indications for the
best therapy to improve therapeutic outcomes in terms
of duration of responses and quality of life.
These should compare Peg-Doxo with other agents
proven to be effective such as pentostatin or gemc-
itabine,18 or design future strategies combining Peg-Doxo
with other active drugs. In particular, studies should
investigate the use of Peg-Doxo as a debulking therapy
before high dose chemotherapy and eventual bone mar-
row or stem cell transplantation.
Authors’ Contributions
SP, SR, NP, PL designed the study; SP, RA, AT, ARS, SM, AS,
GB, AG, GM, GR, GF, AB, MS, NN contributed to the acquisition
of data; MO and GG performed the statistical analysis;
SP,SR,GG,AT analysed the clinical data; GG made the revision of
histologic samples; SP,GG,SR,NP wrote the manuscript; SP and
GG created the tables and figures.
Conflict of Interest
The authors reported no potential conflicts of interest.
Reference
1. Visani G, Guiducci B, D’Adamo F,
Mele A, Nicolini G, Leopardi G, et
al. Cyclophosphamide, pegylated
liposomal doxorubicin, vincristine
and prednisone (CDOP) plus ritux-
imab is effective and well tolerated
in poor performance status elderly
patients with non-Hodgkin’s lym-
phoma. Leuk Lymphoma 2005; 46:
477-9. 
2. Hussein MA, Baz R, Srkalovic G,
Agrawal N, Suppiah R, Hsi E, et al.
Phase 2 study of pegylated liposo-
mal doxorubicin, vincristine, de-
creased-frequency dexamethasone,
and thalidomide in newly diagnosed
and relapsed-refractory multiple
myeloma. Mayo Clin Proc 2006;81:
889-95.
3. Offidani M, Corvatta L, Piersantelli
MN, Visani G, Alesiani F, Brunori M,
et al. Thalidomide, dexamethasone
and pegylated liposomal doxoru-
bicin (ThaDD) for newly diagnosed
multiple myeloma patients over 65
years. Blood 2006;108:2159-64.
4. Trautinger F, Knobler R, Willemze R,
Peris K, Stadler R, et al. EORTC con-
sensus recommendations for the
treatment of mycosis fungoid-
es/Sézary syndrome. Eur J Cancer
2006;42:1014-30.
5. Tsatalas C, Martinis G, Margaritis
D, Spanoudakis E, Kotsianidis I,
Karpouzis, et al. Long-term remis-
sion of recalcitrant tumor-stage
mycosis fungoides following che-
motherapy with pegylated liposo-
mal doxorubicin. J Eur Acad Der-
matol Venereol 2003;17:80-2.
6. Di Lorenzo G, Di Trolio R, Delfino
M, De Placido S. Pegylated liposo-
mal doxorubicin in stage IV B myco-
sis fungoides. Br J Dermatol 2005;
153:183-5.
7. Wollina U, Dummer R, Brockmeyer
NH, Konrad H, Busch JO, Kaatz M,
et al. Multicenter study of pegylated
liposomal doxorubicin in patients
with cutaneous T-cell lymphoma.
Cancer 2003;98:993-1001.
8. Willemze R, Jaffe ES, Burg G,
Cerroni L, Berti E, Swerdlow SH, et
al. WHO-EORTC classification for
cutaneous lymphomas. Blood 2005;
105:3768-85.
9. Cheson BD, Horning SJ, Coiffier B,
Shipp MA, Fisher RI, Connors JM, et
al. Report of an international work-
shop to standardize response criteria
for non-Hodgkin’s lymphomas. NCI
Sponsored International Working
Group. J Clin Oncol 1999;17:1244-
53.
10. Common toxicity criteria (CTC)
and common terminology criteria
for adverse events (CTCAE).
Available from URL: http://ctep.can-
cer.gov/reporting/ctc.html
11. Zachariae H, Thestrup-Pedersen K.
Combination chemotherapy with
bleomycin, cyclophosphamide,
prednisone and etretinate (BCPE) in
advanced mycosis fungoides: a six-
year experience. Acta Derm Vene-
reol 1987;67:433-7.
12. Kaye FJ, Bunn PA Jr, Steinberg SM,
Stocker JL, Ihde DC, Fischmann AB,
et al. A randomized trial comparing
combination electron-beam radia-
tion and chemotherapy with topical
therapy in the initial treatment of
mycosis fungoides. N Engl J Med
1989;321:1784-90.
13. Fierro MT, Doveil GC, Quaglino P,
Savoia P, Verrone A, Bernengo MG.
Combination of etoposide, idaru-
bicin, cyclophosphamide, vincri-
stine, prednisone and bleomycin
(VICOP-B) in the treatment of
advanced cutaneous T-cell lym-
phoma. Dermatology 1997; 194:
268-72.
14. Lundin J, Hagberg H, Repp R,
Cavallin-Stahl E, Freden S, Juliusson
G, et al. Phase 2 study of alemtu-
zumab (anti-CD52 monoclonal anti-
body) in patients with advanced
mycosis fungoides/Sézary syn-
drome. Blood 2003;101:4267-72.
15. Akpek G, Koh HK, Bogen S, O’Hara
C, Foss FM. Chemotherapy with
etoposide, vincristine, doxorubicin,
bolus cyclophosphamide, and oral
prednisone in patients with refracto-
ry cutaneous T-cell lymphoma.
Cancer 1999;86:1368-76.
16. Tirelli U, Carbone A, Zagonel V,
Volpe R, Veronesi A, Galligioni E, et
al. Staging and treatment with
cyclophosphamide, vincristine and
prednisone (CVP) in advanced cuta-
neous T-cell lymphomas. Hematol
Oncol 1986;4:83-90.
17. Fierro MT, Quaglino P, Savoia P,
Verrone A, Bernengo MG. Systemic
polychemotherapy in the treatment
of primary cutaneous lymphomas: a
clinical follow-up study of 81
patients treated with COP or CHOP.
Leuk Lymphoma 1998;31:583-8.
18. Marchi E, Alinari L, Tani M, Stefoni
V, Pimpinelli N, Berti E, et al.
Gemcitabine as frontline treatment
for cutaneous T-cell lymphoma:
phase II study of 32 patients. Cancer
2005;104:2437-41.
19. van Doorn R, Van Haselen CW, van
Voorst Vader PC, Geerts ML, Heule
F, de Rie M, et al. Mycosis fun-
goides: disease evolution and prog-
nosis of 309 Dutch patients. Arch
Dermatol 2000;136:504-10.
